AVACTA GROUP PLC — Share Issue/Capital Change 2024

Apr 26, 2024

National Storage Mechanism | Additional information

RNS Number : 1211M

Avacta Group PLC

26 April 2024

26 April 2024

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Block Listing Six Monthly Return

Avacta Group plc (AIM: AVCT), a life sciences developing innovative, targeted oncology drugs and powerful diagnostics, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:		Avacta Group plc
Name of scheme:		EMI scheme
Period of return:	From:	28 October 2023		27 April 2024
Balance of unallotted securities under scheme(s) from previous return:		797,922
Plus:    The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		113,808
Less:    Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		108,724
Equals:    Balance under scheme(s) not yet issued/allotted at end of period:		911,730

Name of applicant:		Avacta Group plc
Name of scheme:		LTIP scheme
Period of return:	From:	28 October 2023		27 April 2024
Balance of unallotted securities under scheme(s):		5,277,257
Plus:    The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		6,500,000
Less:    Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		2,058,000
Equals:    Balance under scheme(s) not yet issued/allotted at end of period:		11,777,257

Name of contact:	Tony Gardiner, Company Secretary
Telephone number of contact:	+ 44 (0) 1904 217070

Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director	Tel: +44 (0) 1904 21 7070 www.avacta.com
Stifel Nicolaus Europe Limited (Nomad and Joint Corporate Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good	Tel: +44 (0) 207 710 7600 www.stifel.com
Peel Hunt (Joint Corporate Broker) James Steel / Chris Golden / Patrick Birkholm	Tel: +44 (0) 207 418 8900 www.peelhunt.com
ICR Consilium (Media and IR) Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji	avacta@consilium-comms.com

About Avacta Group plc - https://www.avacta.com

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

Avacta has two divisions focused on therapeutics and diagnostics.

Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.

Avacta Diagnostics: focused on supporting healthcare professionals and broadening access to diagnostics.

Avacta has two proprietary platforms, pre|CISION™ and Affimer®.

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.

To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRPPUAGCUPCPUA